Adults 5 to 12, any sex, with BPG Intervention or Control. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Kaufman Assessment Battery for Children 2nd Edition (KABC-II) Mental Processing Index (MPI)Primary· Month 2, month 6
The KABC mental processing index (MPI) is a summary score across domains. The normative mean 100 and standard deviation 15 are based on American norms. Range is 43 to 160. Higher score reflects better outcome.
Month 2
Group
Value
95% CI
BPG, Uganda
77.18
± 0.60
Waitlist Control, Uganda
74.79
± 0.61
BPG, Malawi
71.79
± 0.71
Waitlist Control, Malawi
73.72
± 0.72
Month 6
Group
Value
95% CI
BPG, Uganda
77.27
± 0.60
Waitlist Control, Uganda
76.46
± 0.61
BPG, Malawi
73.40
± 0.69
Waitlist Control, Malawi
73.61
± 0.70
Test of Variables of Attention (TOVA) Attention Deficit Hyperactivity Disorder (ADHD) IndexSecondary· Month 2, month 6
TOVA is a computerized visual continuous performance test used in to screen, diagnose and monitor children and adults at risk for ADHD. TOVA consists of the rapid (tachistoscopic) presentation of a large geometric square on the computer screen with a smaller dark box either in the upper position (signal) or lower position (non-signal). The child is asked to press a switch in response to the signal (measuring vigilance attention), but to withhold responding to the non-signal (measuring impulsivity). The potential range of the TOVA ADHD index is from -10 to 10, higher score is better.
Month 2
Group
Value
95% CI
BPG, Uganda
-1.21
± 0.21
Waitlist Control, Uganda
-1.08
± 0.21
BPG, Malawi
-2.63
± 0.25
Waitlist Control, Malawi
-2.35
± 0.25
Month 6
Group
Value
95% CI
BPG, Uganda
-0.81
± 0.21
Waitlist Control, Uganda
-0.83
± 0.21
BPG, Malawi
-2.23
± 0.24
Waitlist Control, Malawi
-2.15
± 0.24
Cognitive State (CogState) Correct Moves Per SecondSecondary· Month 2, month 6
CogState presents a 30-minute session that includes playing cards in a game-like manner to assess memory, attention, discrimination learning, and executive function that is non-language dependent. The number of correct moves per second during maze learning reflects executive functioning/planning. The range is from 0 to 5. Higher number reflects better outcome.
Month 2
Group
Value
95% CI
BPG, Uganda
0.23
± 0.01
Waitlist Control, Uganda
0.21
± 0.01
BPG, Malawi
0.20
± 0.01
Waitlist Control, Malawi
0.18
± 0.01
Month 6
Group
Value
95% CI
BPG, Uganda
0.27
± 0.01
Waitlist Control, Uganda
0.25
± 0.01
BPG, Malawi
0.23
± 0.01
Waitlist Control, Malawi
0.22
± 0.01
Sponsor's own description
The investigators will use Brain Power Games as a neurocognitive "stress test" or medical "challenge" test, in order to evaluate or improve brain/behavior functional integrity in HIV-affected children. This dual use of BPG is a key innovative feature. Each of the 5 core BPG games lasts 10 minutes and trains fine motor, monitoring/attention, visual/auditory working memory, spatial navigational learning.
The investigator's central hypothesis is that the BPG performance gains will be improved compared to waitlist control for children in Uganda and Malawi.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michigan State University
Last refreshed: 20 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03878147.